Phase I study of the irreversible FGFR inhibitor (i) futibatinib (FBN; TAS-120) in Japanese patients (pts) with advanced (adv) solid tumours
Morizane, C., Kojima, T., Kuboki, Y., Bando, H., Matsubara, N., Shitara, K., Yoh, K., Hirai, H., Kato, T., Doi, T.Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.658
Date:
September, 2020
Fichier:
PDF, 77 KB
2020
File converter
Plus de résultats de recherche
More benefits 
